 Part B will comprise an ascending multiple dose, sequential group study. 16 subjects will be studied in 2 groups Groups B1 to B2, each group consisting of 8 subjects 6 subjects will receive NEO6860 and 2 will receive placebo receiving 5 days of therapy with a dose schedule to be determined during Part A. 